Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells

By S. Venugopal, Sridevi Devaraj, I. Yuhanna, P. Shaul, I. Jialal. Circulation, 2002

896 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/b6297d7b80ad88e541376868fc4c13cfb469b6ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Richard J. Johnson
2. Christian K. Roberts
3. R. J. Barnard
4. M. Quon

In Immunology

1. Richard J. Johnson
2. E. Schiffrin

In Physiology

1. Richard J. Johnson
2. Christian K. Roberts
3. R. J. Barnard
4. E. Schiffrin
5. M. Quon
6. Gustavo Saposnik

Citations in the corpus

• IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. (2005, background): “The fact that IL-6 promotes production of CRP, a protein known to decrease endothelial nitric oxide synthase (eNOS) expression [62], may be a reason why IL-6 has been reported to contribute to the development of atherosclerosis through various metabolic, endothelial and coagulant mechanisms [63].”
• Effects of exercise and diet on chronic disease. (2005, background): “Elevated CRP is associated with decreased nitric oxide (NO) bioavailability in human endothelial cells (395, 396), induces plasminogen activator inhibitor (82), and is independently Invited Review”
• Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2014, background): “In addition, higher levels of acute phase reactants such as C-reactive protein may decrease endothelial cell production of nitric oxide, which may in turn instigate a cascade of events leading to vasoconstriction, leukocyte adherence, platelet activation, oxidation, and thrombosis.(333,334) Attenuat”
• Cardiovascular actions of insulin. (2007, background): “In addition to being a marker of inflammation, CRP may have biological actions to inhibit insulin-evoked NO production in endothelial cells through mechanisms involving phosphorylation of IRS-1 at Ser(307) (mediated by syk, RhoA, and JNK) (284) and decreased expression of eNOS (285).”
• C-reactive protein (2012, neutral): “It has also been reported that CRP inhibits endothelial nitric oxide synthase (eNOS) activity [3,4].”
• Endothelial dysfunction. (2004, background): “Indeed, C-reactive protein (CRP) has been shown to decrease eNOS activity (32,33).”